Biodesix Q3 revenue misses estimates on seasonality impact, project delays
BDSX•Biodesix Q3 revenue rose 10% year over year to $24.04 million, below the $27.49 million analyst estimate. The company revised its 2026 revenue outlook to $101 million-$103 million.
1. Revenue and outlook
Biodesix reported Q3 revenue of $24.04 million, up 10% year over year and below the $27.49 million analyst consensus. Its net loss was $8.03 million, while its adjusted EBITDA loss improved 16% year over year. The company revised its 2026 revenue guidance to $101 million-$103 million and expects gross margins of approximately 80%.
2. Factors affecting results
CEO Scott Hutton cited fewer contributing sales representatives than planned, greater-than-anticipated seasonality—primarily in primary care—and delays in external customer dependencies. The delays postponed the start of Development Services projects and related revenue recognition.
